Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy

Lance C. Pagliaro, Afsaneh Keyhani, Dallas Williams, Denise Woods, Baoshun Liu, Paul Perrotte, Joel W. Slaton, James A. Merritt, H. Barton Grossman, Colin P. Dinney

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (10 10 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

Original languageEnglish (US)
Pages (from-to)2247-2253
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number12
DOIs
StatePublished - Jun 15 2003
Externally publishedYes

Fingerprint

Intravesical Administration
p53 Genes
Urinary Bladder Neoplasms
Genetic Therapy
Urinary Bladder
Transitional Cell Carcinoma
Patient Transfer
bcl-2-Associated X Protein
Cystectomy
Reverse Transcriptase Polymerase Chain Reaction
Transgenes
Adenoviridae
Outpatients
Epithelium
Biopsy
Safety
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer : A phase I study of p53 gene therapy. / Pagliaro, Lance C.; Keyhani, Afsaneh; Williams, Dallas; Woods, Denise; Liu, Baoshun; Perrotte, Paul; Slaton, Joel W.; Merritt, James A.; Grossman, H. Barton; Dinney, Colin P.

In: Journal of Clinical Oncology, Vol. 21, No. 12, 15.06.2003, p. 2247-2253.

Research output: Contribution to journalArticle

Pagliaro, LC, Keyhani, A, Williams, D, Woods, D, Liu, B, Perrotte, P, Slaton, JW, Merritt, JA, Grossman, HB & Dinney, CP 2003, 'Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy', Journal of Clinical Oncology, vol. 21, no. 12, pp. 2247-2253. https://doi.org/10.1200/JCO.2003.09.138
Pagliaro, Lance C. ; Keyhani, Afsaneh ; Williams, Dallas ; Woods, Denise ; Liu, Baoshun ; Perrotte, Paul ; Slaton, Joel W. ; Merritt, James A. ; Grossman, H. Barton ; Dinney, Colin P. / Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer : A phase I study of p53 gene therapy. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 12. pp. 2247-2253.
@article{3e67060351ae4a45a7a5b5eeab26ad81,
title = "Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy",
abstract = "Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (10 10 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.",
author = "Pagliaro, {Lance C.} and Afsaneh Keyhani and Dallas Williams and Denise Woods and Baoshun Liu and Paul Perrotte and Slaton, {Joel W.} and Merritt, {James A.} and Grossman, {H. Barton} and Dinney, {Colin P.}",
year = "2003",
month = "6",
day = "15",
doi = "10.1200/JCO.2003.09.138",
language = "English (US)",
volume = "21",
pages = "2247--2253",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer

T2 - A phase I study of p53 gene therapy

AU - Pagliaro, Lance C.

AU - Keyhani, Afsaneh

AU - Williams, Dallas

AU - Woods, Denise

AU - Liu, Baoshun

AU - Perrotte, Paul

AU - Slaton, Joel W.

AU - Merritt, James A.

AU - Grossman, H. Barton

AU - Dinney, Colin P.

PY - 2003/6/15

Y1 - 2003/6/15

N2 - Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (10 10 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

AB - Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (10 10 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0038826049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038826049&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.09.138

DO - 10.1200/JCO.2003.09.138

M3 - Article

C2 - 12805322

AN - SCOPUS:0038826049

VL - 21

SP - 2247

EP - 2253

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -